Redeye: Hansa Biopharma - Update after Q1 with our revised outlook
Redeye updates its outlook on Hansa Biopharma, anticipating gradual launch support during 2023 and supporting pipeline progress over the next 12 months. We make a negative revision after the recent Q1 2023 result mainly because Hansa is experiencing a period of slower patient enrolment despite the expanding market access. Our Base Case is SEK165 (175) with a Bull Case of SEK390 (400) and a Bear Case of SEK45 (45).
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/